His primary scientific interests are in Melanoma, Internal medicine, Surgery, Oncology and Ipilimumab. His work carried out in the field of Melanoma brings together such families of science as Cancer and Clinical trial. His Internal medicine study frequently draws parallels with other fields, such as Gastroenterology.
The study incorporates disciplines such as Cobimetinib and Hazard ratio in addition to Surgery. In his study, which falls under the umbrella issue of Hazard ratio, Regimen is strongly linked to Placebo. The Sunitinib research Axel Hauschild does as part of his general Oncology study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
Axel Hauschild mainly focuses on Internal medicine, Melanoma, Oncology, Surgery and Dermatology. He combines topics linked to Gastroenterology with his work on Internal medicine. Axel Hauschild has researched Melanoma in several fields, including Cancer, Adjuvant therapy, Ipilimumab and Immunology.
His Oncology research includes themes of Metastatic melanoma, Vemurafenib and Phases of clinical research, Chemotherapy, Dacarbazine. His Surgery research integrates issues from Adverse effect, Alpha interferon and Hazard ratio. The Dermatology study combines topics in areas such as Skin cancer and Pathology.
Axel Hauschild spends much of his time researching Internal medicine, Oncology, Melanoma, In patient and Artificial intelligence. Within one scientific family, Axel Hauschild focuses on topics pertaining to Placebo under Internal medicine, and may sometimes address concerns connected to Hazard ratio. His Oncology research incorporates themes from Metastatic melanoma, Vemurafenib, Dabrafenib, Clinical trial and Trametinib.
Axel Hauschild focuses mostly in the field of Melanoma, narrowing it down to topics relating to Immune checkpoint inhibitors and, in certain cases, Oncolytic virus and Randomized controlled trial. His study in Artificial intelligence is interdisciplinary in nature, drawing from both University hospital, Medical diagnosis and Skin cancer. Axel Hauschild combines subjects such as Targeted therapy and Dacarbazine with his study of Cobimetinib.
Axel Hauschild mostly deals with Internal medicine, Melanoma, Oncology, Artificial intelligence and Skin cancer. His work is dedicated to discovering how Internal medicine, Placebo are connected with Adjuvant and other disciplines. His work in Melanoma addresses subjects such as Stage, which are connected to disciplines such as Cutaneous melanoma.
His study looks at the relationship between Oncology and topics such as Survival rate, which overlap with Efficacy and Cancer immunotherapy. As part of one scientific family, Axel Hauschild deals mainly with the area of Dabrafenib, narrowing it down to issues related to the Trametinib, and often Randomized controlled trial. His Phases of clinical research study combines topics in areas such as Anti pd 1, Dacarbazine and Monoclonal.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen.
The New England Journal of Medicine (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day.
The New England Journal of Medicine (2011)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary.
The Lancet (2012)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski.
The New England Journal of Medicine (2015)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko.
The New England Journal of Medicine (2014)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber;Katharina C. Kähler;Axel Hauschild.
Journal of Clinical Oncology (2012)
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulic;Michael R. Migden;Anthony E. Oro;Luc Dirix.
The New England Journal of Medicine (2012)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko.
The Lancet (2015)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer.
The New England Journal of Medicine (2016)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin.
Lancet Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: